FIELD: biotechnologies.
SUBSTANCE: by the recombinant method a line of cells CHO[V3D] is produced, which are transformed with plasmid pV3D, coding the human vessel endothelium growth factor, isoform A165, with C-terminal 3xDED-epitope (SEQ ID NO: 1), which is able to produce a biologically active recombinant protein VEGF-A165 of humans with C-terminal 3xDED-epitope in the amount of at least 0.2 mg 1 l of medium for 72 hours with 1 ml of growth medium per 5 cm2 of single-layer culture. The cell line is deposited in the All-Russian Collection of Industrial Microorganisms VKPM under the registration number VKPM H-123.
EFFECT: no impact at biological activity of protein and possibility to do protein treatment.
4 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) SECRETING Escherichia coli BL21 (pVEGF-A165) CELL STRAIN | 2008 |
|
RU2395568C2 |
| PEPTIDE DED AND ITS APPLICATION FOR IDENTIFICATION AND/OR PURIFICATION OF RECOMBINANT PROTEINS, VECTOR pDED | 2007 |
|
RU2380373C2 |
| VEGF BINDING V93 NANOANTIBODY AND METHOD OF OBTAINING SAID ANTIBODY, V93-CODING NUCLEOTIDE SEQUENCE AND VECTOR CONTAINING SAID SEQUENCE, ENDOTHELIAL CELL PROLIFERATION INHIBITION METHOD | 2008 |
|
RU2395522C1 |
| VEGF BINDING V9 NANOANTIBODY AND METHOD OF OBTAINING SAID ANTIBODY, V9-CODING NUCLEOTIDE SEQUENCE AND VECTOR CONTAINING SAID SEQUENCE, ENDOTHELIAL CELL PROLIFERATION INHIBITION METHOD | 2008 |
|
RU2395521C1 |
| DOUBLE-TARGETED ANTIBODY IN NEW FORM AND USING IT | 2009 |
|
RU2520824C2 |
| METHOD OF PRODUCING AFLIBERCEPT | 2016 |
|
RU2732237C2 |
| NOVEL DUAL-TARGETED PROTEINS SPECIFICALLY BINDING TO DLL4 AND VEGF, AND USE THEREOF | 2014 |
|
RU2648154C2 |
| C-HALB CELL LINE WHICH SECRETE HUMAN RECOMBINANT ALBUMIN | 2019 |
|
RU2719152C1 |
| FGF-R-Fc FUSED PROTEIN AND USE THEREOF | 2012 |
|
RU2560573C2 |
| ANTIANGIOGENIC INDUCER FUSION PROTEIN AND USING IT | 2012 |
|
RU2560589C2 |
